Packaging for High-Value Oncology Drugs: Ensuring Safety, Stability, and Compliance
Introduction: The Rising Stakes in Oncology Drug Packaging
The oncology therapeutics landscape is undergoing a profound transformation. Antibody-drug conjugates (ADCs), once considered an experimental approach, are now one of the fastest-growing segments in cancer therapeutics, with more than 23 approved products globally and over 400 clinical programmes in development. The ADC market alone is projected to grow from approximately $20 billion today to $60 billion by 2030. Meanwhile, the broader oncology drug kit packaging market is experiencing robust growth at a CAGR of 9.2%, driven by the increasing global cancer burden, rising adoption of combination therapies, and the need for advanced, patient-centric packaging solutions.
For pharmaceutical packaging manufacturers like Vialab Pharmaceutical Packaging Co., Ltd. , this growth represents both opportunity and responsibility. High-value oncology drugs—whether biologics, ADCs, or small-molecule chemotherapeutics—demand packaging that goes far beyond simple containment. These therapies are often highly sensitive to temperature, oxygen, light, vibration, and contamination. A packaging failure can lead to product loss, batch rejection, supply disruption, or—most critically—patient harm.
This article explores the unique packaging requirements for high-value oncology drugs, examining regulatory frameworks, material science considerations, and the critical role of container closure integrity in protecting these life-saving therapies.
The Unique Challenges of Oncology Drug Packaging
Biologics and Their Sensitivity
Biologic oncology drugs create different packaging challenges from traditional small-molecule drugs. They can be highly sensitive to temperature, oxygen, light, vibration, contamination, and interaction with packaging surfaces. For this reason, the industry’s packaging focus is moving from simple containment toward active protection of medicine quality throughout filling, storage, transport, and administration.
Many oncology biologics require lyophilization (freeze-drying) to achieve adequate stability, while liquid formulations can be affected by glass leachables. Additionally, light sensitivity presents further hurdles—some therapies are particularly sensitive to light, which can compromise their stability, efficacy, and shelf life. Traditional secondary packaging is often no longer sufficient to safeguard these drug products.
ADCs: A Dual-Risk Profile
Antibody-drug conjugates combine biologic antibodies with highly potent small-molecule payloads, creating a dual-risk profile that demands advanced containment, strict environmental controls, and highly validated packaging workflows. These complex and sensitive drugs require well-suited containers to prevent degradation due to linker instability, mAb sensitivity, cytotoxicity, and light sensitivity.
Secondary packaging is no longer a support function in ADC supply chains—it is a critical component of product safety, stability, and regulatory compliance. Packaging systems must maintain controlled conditions across storage and transport. Any deviation can impact product integrity and patient safety, making validation and process control essential.
Cold Chain and Temperature Control
Many oncology drugs—particularly biologics, cell therapies, and mRNA-based cancer vaccines—require strict temperature control throughout the supply chain. Some mRNA products may degrade quickly at ambient conditions, necessitating cold-chain logistics and ultra-low temperature freezers. CAR-T cells and other advanced therapies are often cryopreserved at ultra-low temperatures, typically below -150°C, using liquid nitrogen vapor shippers. Packaging for these therapies must be specially designed to withstand extreme temperatures and physical shocks during transit.
Regulatory Framework: USP, EP, and ICH Standards
Oncology drug packaging must comply with an evolving regulatory landscape designed to enhance global harmonization, patient safety, and supply chain integrity. The most important regulations for pharmaceutical packaging include USP, Ph.Eur., and ICH Q1A standards.
USP Packaging and Storage Requirements
Every monograph in the USP–NF must have packaging and storage requirements. For active pharmaceutical ingredients (APIs), the choice would be a tight or well-closed container (as specified in the monograph), and, where needed, a light-resistant container. These standards ensure that containers, closures, and labeling maintain drug integrity and comply with international safety norms.
ICH Q5C and Stability Testing
ICH Q5C mandates that the packaging system be suitable to maintain product stability throughout the shelf life. Pharmaceutical companies must demonstrate that packaging can maintain product sterility and stability over the full shelf life of the medicine. This requires extensive validation, traceability, and quality documentation.
Extractables and Leachables (E&L) Testing
E&L testing has become essential in pharmaceutical packaging, as FDA, EMA, and ICH regulations drive compliance and ensure safety for biologics, medical devices, and drug delivery systems. For oncology drugs, where patients may receive multiple doses over extended periods, the potential for extractables and leachables to impact patient safety is a critical concern. Container and closure systems must be proven compatible with the drug product, inert to its ingredients, and free from risks of contamination.
Container Closure Integrity: The Foundation of Drug Protection
Container Closure Integrity Testing (CCIT) is a critical evaluation of whether the packaging system effectively seals the pharmaceutical product against environmental ingress. It ensures protection from contaminants such as moisture, oxygen, and microbes, especially over extended storage periods.
Why CCIT Matters for Oncology Drugs
Products stored for 12–36 months or longer must retain their integrity under designated climatic conditions. Over time, seals may weaken, closures may deform, or barrier materials may degrade. Without validated CCIT, there is no assurance that the packaging will continue to protect the product during its entire labeled shelf life.
Undetected breaches in container closure can cause microbial growth, oxidation, loss of potency, or physical changes like evaporation. Such failures may only be discovered during patient use or regulatory inspection—often too late to prevent adverse outcomes or recalls.
CCIT Methods and Regulatory Expectations
The ECA Visual Inspection Working Group has issued best practice recommendations for CCIT of parenteral drug products, defining a lifecycle CCI control strategy that integrates qualification/validation, routine controls, supplier management, and stability studies.
For non-fusion-sealed containers such as vials and prefilled syringes, validated CCIT methods should be applied within the stability program to confirm integrity over shelf life. Regulatory agencies require CCIT validation for critical dosage forms such as parenterals, inhalers, and biologics, and expect robust justification for container integrity over time.
CCIT data must be included in Module 3.2.P.7 (Container Closure System) of the CTD and referenced in stability summaries. During audits, regulators verify whether CCIT methods are validated, sensitive enough, and integrated into the stability program—particularly for sterile or high-risk products.
Material Selection: Glass Vials and Tubing
Glass vials remain the most widely used primary containers for the packaging of parenteral products due to their optical clarity, general inertness, and hermetic properties. For oncology drugs, the quality of glass packaging is paramount.
ISO Standards for Pharmaceutical Glass
ISO 11418-7 specifies the form, dimensions, and capacities of glass vials for pharmaceutical preparations, as well as the material from which such containers shall be made and the performance requirements. This standard applies to colorless or amber glass vials made from borosilicate or soda-lime-silica glass, made from glass tubing and intended to be used in the packaging, storage, or transportation of pharmaceutical products.
ISO 8362-1 further specifies the form, dimensions, and capacities of glass vials for injectable preparations. Injection vials made of glass tubing and containing neck finishes with blow back have been added to the standard.
Glass Delamination: A Critical Risk
Under certain circumstances, glass vials can pose safety concerns. Glass delamination—the occurrence of thin, shiny glass layers (lamellae) that detach from the interior surface of a glass container and float in the contact liquid—has been the subject of many product recalls and regulatory advisories.
For high-value oncology drugs, the risk of delamination is particularly concerning. Interaction between the drug product and the inner surface of the glass vial can lead to the formation of glass particles that may be administered to patients. Advanced glass technologies, such as boron-free glass compositions designed specifically for pharmaceutical use, have been developed to eliminate delamination.
Vialab’s Capabilities in Glass Packaging
Vialab specializes in the manufacture of glass vials and tubes of parenteral grade with precise dimensions. Our production capabilities encompass both clear and amber glass options, allowing us to meet the light-protection requirements of photosensitive oncology drugs. Every vial is manufactured to meet strict pharmaceutical standards, with rigorous quality control throughout the production process.
Injection Pens and Prefilled Syringes: Patient-Centric Delivery
The shift toward patient-administered therapies has driven significant growth in prefilled syringes and injection pens. The prefilled syringes segment leads the pharmaceutical packaging market, accounting for 32.6% of the market share in 2024, due to their benefits in patient compliance and safety.
Benefits for Oncology Patients
Prefilled syringes have become more popular because they now work better with autoinjectors and other drug delivery devices, providing solutions for home medical treatment. For oncology patients who may require frequent injections, these delivery systems offer convenience, accuracy, and reduced risk of dosing errors.
Packaging Considerations
For oncology drugs in prefilled syringe and injection pen formats, packaging must ensure:
- Sterile barrier integrity throughout shelf life
- Compatibility with the drug product (minimizing extractables and leachables)
- Dimensional precision for reliable device function
- Tamper-evident features to ensure product authenticity
Prefilled syringes are now explicitly integrated into CCI concepts and validation frameworks, with requirements for stopper and tip-cap setting validation, PPQ sampling for CCI, and corresponding process controls.
Vialab’s Injection Pen Solutions
Vialab offers both disposable and reusable injection pens designed to meet the demanding requirements of oncology drug delivery. Our pens are engineered with precision to ensure accurate dosing and reliable performance, supporting patient adherence and therapeutic outcomes.
Elastomer Closures: The Critical Seal
Elastomer closures—stoppers for vials, cartridges, and prefilled syringes—are mission-critical components in injectable drug packaging. For oncology drugs, the choice of elastomer closure can significantly impact container closure integrity and product stability.
Performance Requirements
Vial containment systems with advanced elastomer stoppers offer substantial performance benefits, including enhanced dimension control, reduced particle levels, and the use of fluoropolymer films that reduce potential interactions with drug products. Container closure integrity is essential to protecting drug product and satisfying regulatory agencies.
Vialab’s Capabilities
Vialab manufactures aluminum and aluminum-plastic caps with tamper-evident features in various sizes. Our closures are designed to maintain container closure integrity throughout the product lifecycle, from filling through patient administration. Each closure is manufactured to precise specifications, ensuring consistent performance batch after batch.
Sterile Vials: Ready-to-Use Solutions
The demand for ready-to-use (RTU) packaging solutions is growing across the pharmaceutical industry. RTU vials—pre-washed and sterilized—offer significant advantages for oncology drug manufacturers:
- Reduced time-to-market: Eliminating the need for in-house washing and sterilization
- Lower risk of contamination: Processing in controlled, validated environments
- Improved supply chain efficiency: Ready-to-fill formats streamline operations
Vialab offers sterile vials in ready-to-use formats, including wash-and-sterilized options. Each vial is manufactured and processed in cleanroom facilities to meet ISO and GMP standards, ensuring consistent quality and integrity for global healthcare partners.
Sustainability in Oncology Drug Packaging
While patient safety and drug stability remain the primary concerns, sustainability is emerging as an important consideration in pharmaceutical packaging strategies. Because high-value oncology products require high-containment environments, sustainability improvements are often less about material reduction and more focused on design optimization and operational efficiency.
This includes rightsizing packaging components, reducing non-essential materials, and improving logistics efficiency through lighter configurations and optimized cold-chain systems. High-containment environments are energy-intensive, making HVAC optimization, digital monitoring, and process efficiency critical levers for reducing environmental impact while maintaining compliance standards.
Vialab is committed to sustainable manufacturing practices, optimizing our production processes to minimize waste and environmental impact without compromising the quality and integrity of our packaging solutions.
Conclusion: Partnering for Excellence in Oncology Drug Packaging
The packaging of high-value oncology drugs requires a level of precision, expertise, and commitment that goes far beyond conventional pharmaceutical packaging. From the selection of glass tubing that resists delamination to the validation of container closure integrity over extended shelf lives, every decision impacts patient safety and therapeutic outcomes.
As biologics and high-value therapeutics continue to grow, expectations for packaging are becoming more demanding. The value of the material is often high, while the tolerance for failure is very low. Packaging suppliers are being asked to provide stronger technical evidence, tighter process control, and materials designed for high-value therapies.
Vialab Pharmaceutical Packaging Co., Ltd. stands ready to meet these challenges. With advanced production lines, cleanroom facilities, and a commitment to ISO and GMP compliance, we deliver the quality, integrity, and reliability that oncology drug manufacturers demand. Our comprehensive product portfolio—from injection pens and glass vials to sterile vials and tamper-evident closures—provides a single-source solution for pharmaceutical packaging needs.
Whether you are developing a novel ADC, a biologic immunotherapy, or a targeted small-molecule therapy, Vialab has the expertise and capabilities to protect your product from development through commercial distribution. Contact us today to learn how we can support your oncology drug packaging requirements.